<DOC>
	<DOC>NCT01949324</DOC>
	<brief_summary>This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.</brief_summary>
	<brief_title>A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<criteria>Participant must be offered sufficient opportunity to review and to understand the informed consent form, agree to the form's contents and sign the protocol's informed consent Participant must have at least one study eye with a positive diagnosis of MacTel Type 2 Participant must have an IS/OS PR break in the study eye(s) and en face ellipsoid zone (area of IS/OS loss) as measured by SDOCT between 0.16 mm2 and 4.00 mm2 If female, participant must be incapable of pregnancy If male, participant must agree to use an effective form of birth control during the study Participant is unable to provide informed consent Participant is less than 21 years of age or greater than 80 years of age Participant is medically unable to comply with study procedures or followup visits Participant was a study subject in any other clinical trial of an intervention (drug or device) within the last 6 months Participant is pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MacTel</keyword>
</DOC>